151 related articles for article (PubMed ID: 31514337)
1. TGFBI Protein Is Increased in the Urine of Patients with High-Grade Urothelial Carcinomas, and Promotes Cell Proliferation and Migration.
Lang K; Kahveci S; Bonberg N; Wichert K; Behrens T; Hovanec J; Roghmann F; Noldus J; Tam YC; Tannapfel A; Käfferlein HU; Brüning T
Int J Mol Sci; 2019 Sep; 20(18):. PubMed ID: 31514337
[TBL] [Abstract][Full Text] [Related]
2. Epirubicin suppresses proliferative and metastatic potential by downregulating transforming growth factor-β-induced expression in urothelial carcinoma.
Shang D; Song B; Liu Y
Cancer Sci; 2018 Apr; 109(4):980-987. PubMed ID: 28940965
[TBL] [Abstract][Full Text] [Related]
3. TGFBI Expression in Cancer Stromal Cells is Associated with Poor Prognosis and Hematogenous Recurrence in Esophageal Squamous Cell Carcinoma.
Ozawa D; Yokobori T; Sohda M; Sakai M; Hara K; Honjo H; Kato H; Miyazaki T; Kuwano H
Ann Surg Oncol; 2016 Jan; 23(1):282-9. PubMed ID: 25448803
[TBL] [Abstract][Full Text] [Related]
4. Expression of CD147, BIGH3 and Stathmin and their potential role as diagnostic marker in patients with urothelial carcinoma of the bladder.
Bhagirath D; Abrol N; Khan R; Sharma M; Seth A; Sharma A
Clin Chim Acta; 2012 Oct; 413(19-20):1641-6. PubMed ID: 22626996
[TBL] [Abstract][Full Text] [Related]
5. Soluble chemokine (C-X-C motif) ligand 16 (CXCL16) in urine as a novel biomarker candidate to identify high grade and muscle invasive urothelial carcinomas.
Lang K; Bonberg N; Robens S; Behrens T; Hovanec J; Deix T; Braun K; Roghmann F; Noldus J; Harth V; Jöckel KH; Erbel R; Tam YC; Tannapfel A; Käfferlein HU; Brüning T
Oncotarget; 2017 Dec; 8(62):104946-104959. PubMed ID: 29285224
[TBL] [Abstract][Full Text] [Related]
6. Transforming growth factor beta-induced (TGFBI) is an anti-adhesive protein regulating the invasive growth of melanoma cells.
Nummela P; Lammi J; Soikkeli J; Saksela O; Laakkonen P; Hölttä E
Am J Pathol; 2012 Apr; 180(4):1663-74. PubMed ID: 22326753
[TBL] [Abstract][Full Text] [Related]
7. Significance of suppressor of cytokine signaling-3 expression in bladder urothelial carcinoma in relation to proinflammatory cytokines and tumor histopathological grading.
Gaballah HH; Shafik NM; Wasfy RE; Abou Farha MO
Asian Pac J Cancer Prev; 2015; 16(1):307-14. PubMed ID: 25640370
[TBL] [Abstract][Full Text] [Related]
8. Expression of parvin-beta is a prognostic factor for patients with urothelial cell carcinoma of the upper urinary tract.
Wu CF; Ng KF; Chen CS; Chang PL; Chuang CK; Weng WH; Liao SK; Pang ST
Br J Cancer; 2010 Sep; 103(6):852-60. PubMed ID: 20736946
[TBL] [Abstract][Full Text] [Related]
9. High stromal transforming growth factor β-induced expression is a novel marker of progression and poor prognosis in gastric cancer.
Suzuki M; Yokobori T; Gombodorj N; Yashiro M; Turtoi A; Handa T; Ogata K; Oyama T; Shirabe K; Kuwano H
J Surg Oncol; 2018 Nov; 118(6):966-974. PubMed ID: 30260476
[TBL] [Abstract][Full Text] [Related]
10. Methylomics analysis identifies ZNF671 as an epigenetically repressed novel tumor suppressor and a potential non-invasive biomarker for the detection of urothelial carcinoma.
Yeh CM; Chen PC; Hsieh HY; Jou YC; Lin CT; Tsai MH; Huang WY; Wang YT; Lin RI; Chen SS; Tung CL; Wu SF; Chang DC; Shen CH; Hsu CD; Chan MW
Oncotarget; 2015 Oct; 6(30):29555-72. PubMed ID: 26320192
[TBL] [Abstract][Full Text] [Related]
11. The value of the UroVysion® FISH assay in the risk-stratification of patients with "atypical urothelial cells" in urinary cytology specimens.
Virk RK; Abro S; de Ubago JMM; Pambuccian SE; Quek ML; Wojcik EM; Mehrotra S; Chatt GU; Barkan GA
Diagn Cytopathol; 2017 Jun; 45(6):481-500. PubMed ID: 28397365
[TBL] [Abstract][Full Text] [Related]
12. CXCL5 is a potential diagnostic and prognostic marker for bladder cancer patients.
Zhu X; Qiao Y; Liu W; Wang W; Shen H; Lu Y; Hao G; Zheng J; Tian Y
Tumour Biol; 2016 Apr; 37(4):4569-77. PubMed ID: 26503215
[TBL] [Abstract][Full Text] [Related]
13. Human Epidermal Growth Factor Receptor 2 Overexpression in Micropapillary and Other Variants of Urothelial Carcinoma.
Behzatoğlu K; Yörükoğlu K; Demir H; Bal N
Eur Urol Focus; 2018 Apr; 4(3):399-404. PubMed ID: 28753766
[TBL] [Abstract][Full Text] [Related]
14. The small conductance calcium-activated potassium channel 3 (SK3) is a molecular target for Edelfosine to reduce the invasive potential of urothelial carcinoma cells.
Steinestel K; Eder S; Ehinger K; Schneider J; Genze F; Winkler E; Wardelmann E; Schrader AJ; Steinestel J
Tumour Biol; 2016 May; 37(5):6275-83. PubMed ID: 26619845
[TBL] [Abstract][Full Text] [Related]
15. Synergistic inhibitory effects of 5-aza-2'-deoxycytidine and cisplatin on urothelial carcinoma growth via suppression of TGFBI-MAPK signaling pathways.
Shang D; Li G; Zhang C; Liu Y
Biochem Cell Biol; 2022 Apr; 100(2):115-124. PubMed ID: 34890285
[TBL] [Abstract][Full Text] [Related]
16. Enhanced Expression of TGFBI Promotes the Proliferation and Migration of Glioma Cells.
Guo SK; Shen MF; Yao HW; Liu YS
Cell Physiol Biochem; 2018; 49(3):1097-1109. PubMed ID: 30196284
[TBL] [Abstract][Full Text] [Related]
17. Role of isoenzyme M2 of pyruvate kinase in urothelial tumorigenesis.
Zhou H; Wang X; Mo L; Liu Y; He F; Zhang F; Huang KH; Wu XR
Oncotarget; 2016 Apr; 7(17):23947-60. PubMed ID: 26992222
[TBL] [Abstract][Full Text] [Related]
18. Tumor-associated macrophages promote ovarian cancer cell migration by secreting transforming growth factor beta induced (TGFBI) and tenascin C.
Steitz AM; Steffes A; Finkernagel F; Unger A; Sommerfeld L; Jansen JM; Wagner U; Graumann J; Müller R; Reinartz S
Cell Death Dis; 2020 Apr; 11(4):249. PubMed ID: 32312959
[TBL] [Abstract][Full Text] [Related]
19. SH3BGRL3 Protein as a Potential Prognostic Biomarker for Urothelial Carcinoma: A Novel Binding Partner of Epidermal Growth Factor Receptor.
Chiang CY; Pan CC; Chang HY; Lai MD; Tzai TS; Tsai YS; Ling P; Liu HS; Lee BF; Cheng HL; Ho CL; Chen SH; Chow NH
Clin Cancer Res; 2015 Dec; 21(24):5601-11. PubMed ID: 26286913
[TBL] [Abstract][Full Text] [Related]
20. Uridine 5'diphospho-glucuronosyltransferase 1A expression as an independent prognosticator in urothelial carcinoma of the upper urinary tract.
Izumi K; Inoue S; Ide H; Fujita K; Mizushima T; Jiang G; Yamaguchi S; Fushimi H; Nonomura N; Miyamoto H
Int J Urol; 2018 May; 25(5):429-435. PubMed ID: 29444544
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
